Dyne Therapeutics, Inc. DYN
16.03
(0.48)
(2.91%)
as of 25 Sep
- Market cap
- $3.1B
- P/E
- 0.0×
Follow DYN
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (81.57%) | (58.89%) | (55.71%) | (60.66%) |
+8 more TTM periods Free account |
|
| (60.29%) | (50.16%) | (47.52%) | (51.81%) | ||
ROIC |
(1,956.27%) | (607.10%) | (2,790.00%) | 0.00% | |
Return on Tangible Assets |
(58.73%) | (45.47%) | (40.57%) | (55.01%) | |
Free Cash Flow per Share |
(2.90) | (2.69) | (3.15) | (2.67) | |
Free Cash Flow |
(480.43) | (443.40) | (405.13) | (378.22) | |
Capital Expenditures |
(2.61) | (1.16) | (1.92) | (2.51) | |
| Other line items | |||||
Cash ROIC |
(26.34%) | (22.19%) | (18.07%) | (23.74%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.92 | 0.98 | 0.90 | 0.89 | |
Depreciation/Fixed assets |
0.04 | 0.03 | 0.01 | (0.01) | |
Capex/Depreciation |
(2.92) | (1.91) | (8.97) | 8.23 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.89) | (2.68) | (3.14) | (2.65) | |
Capex per Share |
(0.02) | (0.01) | (0.01) | (0.02) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates